ATR inhibition also impairs cell cycle progression and selective ATR inhibitors, including ceralasertib (AZD6738) and berzosertib (M6620/VX-970/VE-822), have shown anti-tumor activity both as single agents or in combination with DNA-damaging chemotherapy, irradiation, and PARP inhibitors [92]. The gene discussed is ATR; the disease is neoplasm.